Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-PROMISE: Prospective observational study of first-line nivolumab plus ipilimumab in unresectable hepatocellular carcinoma in Japan
jRCT1031250756Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab and ipilimumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Primary endpoints: Safety profile of grade 3 or higher immune-mediated liver injury, Effectiveness: objective response rate, best overall response, disease control rate and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1031250756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250756.